A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of RVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis

Overview

Journal Thromb Haemost

Publisher Thieme

Specialties Cardiology & Vascular Diseases
Hematology

Date 2023 Feb 9

PMID 36758611

Authors

Benoit Guillet

Abel Hassoun

Benedicte Wibaut

Annie Harroche

Christine Biron-Andreani

Yohan Repesse

Roseline dOiron

Brigitte Tardy

Brigitte Pan Petesch

Pierre Chamouni

Valerie Gay

Marc Fouassier

Claire Pouplard

Cedric Martin

Hasan Catovic

Xavier Delavenne

Affiliations

Soon will be listed here.

Abstract

Background: rVIII-SingleChain is a recombinant factor VIII (FVIII) with increased binding affinity to von Willebrand factor compared with other FVIII products. rVIII-SingleChain is indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A.

Objectives: To collect real-world evidence data from patients treated with rVIII-SingleChain to confirm the efficacy and safety established in the clinical trial program and carry out a population pharmacokinetic (PK) analysis.

Methods: This interim analysis includes data, collected between January 2018 - September 2021, from patients treated with rVIII-SingleChain prophylaxis at French Hemophilia Treatment centers. Data on annualized bleeding rates, dosing frequency, and consumption before and after switching to rVIII-SingleChain were recorded. A population PK analysis was also conducted to estimate PK parameters.

Results: Overall, 43 patients switched to prophylaxis with rVIII-SingleChain either from a previous prophylaxis regimen or from on-demand treatment. Following the switch to rVIII-SingleChain, patients maintained excellent bleed control. After switching to rVIII-SingleChain, most patients maintained or reduced their regimen. Interestingly, a majority of patients treated >2 ×/weekly with a standard half-life FVIII reduced both injection frequency and FVIII consumption with rVIII-SingleChain. A PK analysis revealed a lower clearance of rVIII-SingleChain (1.9 vs. 2.1 dL/h) and a longer half-life both in adolescents/adults ( = 28) and pediatric ( = 6) patients (15.5 and 11.9 hours, respectively vs. 14.5 and 10.3 hours) than previously reported.

Conclusions: Patients who switched to rVIII-SingleChain prophylaxis demonstrated excellent bleed control and a reduction in infusion frequency. A population PK analysis revealed improved PK parameters compared with those reported in the clinical trial.

References

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

Graf L . Extended Half-Life Factor VIII and Factor IX Preparations. Transfus Med Hemother. 2018; 45(2):86-91. PMC: 5939656. DOI: 10.1159/000488060. View

Collins P, Blanchette V, Fischer K, Bjorkman S, Oh M, Fritsch S . Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7(3):413-20. DOI: 10.1111/j.1538-7836.2008.03270.x. View

Pouplard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C . Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. Haemophilia. 2020; 26(2):282-289. DOI: 10.1111/hae.13946. View

Coyle T, Reding M, Lin J, Michaels L, Shah A, Powell J . Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014; 12(4):488-96. PMC: 4265842. DOI: 10.1111/jth.12506. View

Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C . Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2020; 99(11):2689-2698. PMC: 7536163. DOI: 10.1007/s00277-020-04280-3. View

Schmidbauer S, Witzel R, Robbel L, Sebastian P, Grammel N, Metzner H . Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2015; 136(2):388-95. DOI: 10.1016/j.thromres.2015.05.005. View

Van den Bossche D, Peerlinck K, Jacquemin M . New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018; 40 Suppl 1:21-29. DOI: 10.1111/ijlh.12813. View

Berntorp E, Negrier C, Gozzi P, Blaas P, Lethagen S . Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. Haemophilia. 2016; 22(3):389-96. DOI: 10.1111/hae.12887. View

10.

Yan S, Maro G, Desai V, Simpson M . A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020; 26(10):1258-1265. PMC: 10391132. DOI: 10.18553/jmcp.2020.20199. View

11.

Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A . Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2019; 98(9):2035-2044. PMC: 6700041. DOI: 10.1007/s00277-019-03747-2. View

12.

Oldenburg J, Mahlangu J, Kim B, Schmitt C, Callaghan M, Young G . Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017; 377(9):809-818. DOI: 10.1056/NEJMoa1703068. View

13.

Dolan G, Iorio A, Jokela V, Juusola K, Lassila R . Haemophilia in a real-world setting: the value of clinical experience in data collection. Eur J Haematol. 2016; 96 Suppl 82:3-9. DOI: 10.1111/ejh.12715. View

14.

Teitel J, Sholzberg M, Iorio A . Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. Res Pract Thromb Haemost. 2021; 5(2):349-355. PMC: 7938611. DOI: 10.1002/rth2.12476. View

15.

Bonanad S, Nunez R, Poveda J, Kurnik K, Goldmann G, Andreozzi V . Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A. Adv Ther. 2021; 38(9):4872-4884. PMC: 8408075. DOI: 10.1007/s12325-021-01853-0. View

16.

Mahlangu J, Kuliczkowski K, Karim F, Stasyshyn O, Kosinova M, Lepatan L . Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016; 128(5):630-7. PMC: 4974198. DOI: 10.1182/blood-2016-01-687434. View

17.

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

18.

Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E . Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017; 15(12):2461-2465. DOI: 10.1111/jth.13867. View

19.

Gidal B, Clark A, Anders B, Gilliam F . The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy Res. 2016; 129:26-32. DOI: 10.1016/j.eplepsyres.2016.10.020. View

20.

Bukkems L, Preijers T, van Spengler M, Leebeek F, Cnossen M, Mathot R . Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. Thromb Haemost. 2021; 121(6):731-740. DOI: 10.1055/s-0040-1721484. View